Approval of Kynamro

February 15, 2013 by Mark Tracy

The January 2013 approval of Kynamro (mipomirsen) marks the first systemically administered antisense oligonucleotide to reach the market:

http://www.fiercebiotech.com/story/fda-hands-sanofi-isis-approval-hofh-drug-kynamro/2013-01-29